Compare FuelCell Energy Inc (FCEL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Viatris Inc — how do they compare? FuelCell Energy Inc trades at $17.15 (market cap $1.62B), while Viatris Inc trades at $17.27 (market cap $19.44B). The key difference: Viatris Inc is far larger — about 12× FuelCell Energy Inc's market cap, and Viatris Inc pays a 2.88% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| FCEL | VTRS | |
|---|---|---|
Market Cap | $1.62B | $19.44B |
Sector | Industrials | Health |
52-Week High | $36.01 | $17.39 |
52-Week Low | $3.92 | $8.74 |
Enterprise Value | $1.47B | $31.65B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $17.35, down 18.74% over 24 hours, reflecting recent volatility. The stock shows a bearish technical signal with support at $17 and resistance at $21. Fundamentally, the company reported a net loss of $187.90 million on $158.16 million revenue in 2025, with negative profit margins persisting. Recent news highlights a partnership with Siemens for scalable fuel cell solutions and a $225 million stock offering that caused dilution concerns. Analyst consensus is mixed with a $20.75 price target.
FCEL presents high-risk growth potential driven by AI data center energy demand and strategic partnerships, but faces significant challenges including consistent losses, cash burn, and shareholder dilution. The stock's outlook hinges on execution of commercial projects and path to profitability, with substantial downside risk if growth catalysts fail to materialize.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
